On July 05, the Lipid-based Drug Delivery Application Forum was successfully held in Tianfu Life Science Park by Chengdu Hi-tech Investment Biopharmaceutical Park Management Co., Ltd., AVT (Shanghai) Pharmaceutical Technology Co., Ltd., Suzhou Aitesen Pharmaceutical Equipment Co., Ltd. and NanoFCM Inc. The forum aimed to help enterprises gain deeper insights into lipid-based delivery systems, a hot topic in drug innovation.

        The forum facilitated an in-depth discussion on the R&D and production challenges, current industry landscape and development prospects of lipid-based delivery systems. This discussion aimed to equip technicians from participating enterprises with insights into the frontier dynamics of complex formulations and inspire pharmaceutical enterprises to incorporate lipid-based delivery systems in their development or enhancement of new formulations, thereby offering strong support for the R&D and production of high-end complex formulation enterprises in China.

        Numerous experts from the pharmaceutical industry, both upstream and downstream, were invited to the forum. In the forum, they shared their insights on "the R&D and production challenges, current industry landscape and development prospects of lipid-based delivery systems":

Report I: Stimulus-responsive Nano-drugs

        Contents: Malignancy, as a major threat to human health, exhibits limited response to traditional anti-tumor drugs. Consequently, there is an urgent need to develop new drugs to enhance the efficacy of cancer treatment. The report began by addressing the limitations of traditional drugs, and then deeply delved into the advantages and research progress of new-generation targeted cancer therapies. It compared hypoxia-responsive nano-drug delivery systems, providing insights into diagnosing and predicting the effect of radioimmunotherapy. Additionally, the report presented the latest progress in nano-drug research.

Report II: Anti-tumor Nano-drugs

        Contents: Striking a balance between the functionality and translational potential of nano-drugs presents a substantial challenge. How to design simple and efficient nano-drugs has therefore become an urgent problem. The report deeply discussed how to leverage the physicochemical properties of materials and drugs to design more efficient and simple nano-drugs, offering new ideas for the R&D of nano-drugs.

Report III: Core Process and Technological Innovation of Complex Formulations

        Contents: In recent years, liposome drugs, mRNA vaccines and nucleic acid drugs have developed rapidly. Aitesen, through real project cases, shared its challenges and experience with complex formulations such as liposomes, microspheres, and lipid nanoparticles (LNPs) in different stages, such as process scale-up and commercial production.

Report IV: Research Progress of Liposomes in Cancer Therapy

        Contents: The report focused on liposomal anti-tumor drugs in complex formulations. In this report, AVT provided a detailed introduction to the application of lipid-based delivery systems for anti-tumor drugs, encompassing those currently marketed and under development. Furthermore, AVT discussed the potential and future trends in the application of lipid-based delivery systems in new drug R&D.

Report V: Study on Delivery Technology of Innovative mRNA Drugs

        Contents: The report elaborated on the challenges in developing mRNA drug delivery technology and discussed strategies to address these challenges, offering new ideas for the research of mRNA drug delivery technology.

Report VI: Application of Single Molecule Nano Flow Cytometry in Comprehensive Characterization of Lipid-based Nano-drugs

        Contents: The report provided an in-depth introduction to lipid-based nano-drugs, covering their classification, key physicochemical properties, mRNA-LNP analysis technology and NanoFCM technology, from technical details to practical applications. Additionally, the reports shared several practical cases, providing valuable reference for the R&D and application of lipid-based nano-drugs.

        In the future, Chengdu Hi-tech Investment Biopharmaceutical Park Management Co., Ltd. will enhance its support for the diverse development needs of enterprises and provide them with more comprehensive and professional services. This effort aims to advance scientific and technological innovation among these enterprises and make new contributions to regional economic growth.